Company overview
EXO Biologics is a Belgian clinical-stage biotech company developing exosome-based biopharmaceuticals for rare diseases with high unmet needs, including respiratory conditions like bronchopulmonary dysplasia (BPD) in preterm newborns. They offer ExoXpert, a specialized CDMO service for exosome development and GMP manufacturing using the ExoPulse platform. Their pipeline targets inflammatory, neurological, and oncological applications, with lead candidate EXOB-001 in Phase 1/2 trials.
Next generation of nanomedicine therapy is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include exosome cdmo, exo biologics, extracellular vesicles, gmp exosomes, rare disease therapeutics.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Next generation of nanomedicine therapy include Cdmo — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.exobio.be/en/
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- exosome cdmo, exo biologics, extracellular vesicles, gmp exosomes, rare disease therapeutics
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are EXO Biologics' core capabilities in exosome development?
- EXO Biologics provides an innovative drug loading and delivery platform using exosomes, supported by a state-of-the-art GMP manufacturing platform from research to clinical use via ExoPulse technology.
- What regulatory designations has EXO Biologics received?
- EXOB-001 has Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA, Orphan Drug Designation from the EMA, and is in an EMA-authorized Phase 1/2 trial (EVENEW, NCT06279741) for BPD prevention.
- What therapeutic areas and geographies does EXO Biologics serve?
- Focus on rare diseases in respiratory (e.g., BPD), inflammatory bowel, neurology, and oncology; based in Belgium (Liege), conducting trials in Europe (Belgium, Italy), with global CDMO services via ExoXpert.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
